Simon JA, et al. - Authors sought to determine the efficacy and tolerability of ulipristal acetate, a selective progesterone receptor modulator, for treatment of symptomatic uterine leiomyomas. At 5 mg and 10 mg, ulipristal was well tolerated and superior to placebo in rate of and time to amenorrhea in women with symptomatic uterine leiomyomas.